Oral posters
| Aug. 31st 16:30 | Poster session 1 |
| SCREEN A | |
| P11.3 16:30 | Olufolakemi M. COLE Soaps and cleansers and their association with atopic dermatitis severity in adolescents and adults in southwest Nigeria |
| P8.26 16:35 | Erere OTROFANOWEI The efficacy of an emollient/moisturiser in restoring hydration, skin pH and Trans Epidermal Water Loss (TEWL) in patients with Atopic Dermatitis |
| P13.1 16:40 | Alpana MOHTA Assessment of the Effects of a Colloidal Oatmeal-based Eczema Cream on Skin Microbiome and Barrier Function in Mild to Moderate Atopic Dermatitis: A Randomized Clinical Trial |
| P5.12 16:45 | Magdalena BADZIĄG Contact haptens in emollient products – an analysis of the Polish market |
| P10.20 16:50 | Michele RAMIEN Prescribing practices of Canadian clinicians for the treatment of moderate-to-severe atopic dermatitis (AD) in the pediatric population (<12 years old) |
| SCREEN B | |
| P11.4 16:30 | Kathrin THORMANN Implementation and evaluation of a patient action plan for adult patients with atopic dermatitis |
| P10.21 16:35 | Annice HERATIZADEH Usefulness of the German S2k guideline’s checklist criteria for systemic therapy in patients with atopic dermatitis for routine care |
| P10.22 16:40 | Alicja MESJASZ Parental preferences regarding the novel systemic treatment for Atopic Dermatitis in children |
| P5.13 16:45 | Rui CHEN Assessing disease control in patients with atopic dermatitis by using the Atopic Dermatitis Control Tool (ADCT) in daily practice |
| P5.14 16:50 | Junfen ZHANG Validity, reliability, responsiveness, and interpretability of the Recap of atopic eczema (RECAP) questionnaire |
| SCREEN C | |
| P5.15 16:30 | Fandresena Arilala SENDRASOA Treatment patterns of atopic dermatitis medication in children under 2 years of age in Antananarivo, Madagascar |
| P3.1 16:35 | Raden Mohamad Rendy Ariezal EFFENDI Atopic Dermatitis in Indonesian Children: A Case Control Study |
| P13.2 16:40 | Ousmane FAYE on behalf of Mamadou GASSAMA Severe atopic dermatitis treated with wet wrapping: a case reported to the dermatology hospital in Bamako Mali |
| P5.16 16:45 | Muzna Khalfan MASOUD Awareness, Attitude and Quality of Life among Primary Caregivers of Children with Atopic Dermatitis Attending the Regional Dermatology Training Center in Northern Tanzania in 2023 |
| P2.1 16:50 | Tae Woong SEUL Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: 4 years, single-center, retrospective study |
| SCREEN D | |
| P2.2 16:30 | Amina Nomtondo OUEDRAOGO Is the Treatment of Atopic Dermatitis Related to Purchasing Power? Evidence From a Direct Medical Cost Evaluation in Ouagadougou? |
| P5.18 16:35 | Junfen ZHANG Limited health literacy and its associated health outcomes among adults with at least two atopic diseases |
| P9.14 16:40 | Annika VOLKE 12 months prevalence of atopic dermatitis in resource rich countries: a systematic review and meta analysis |
| P8.27 16:45 | Elise Josephina LEEMAN Health literacy in patients with atopic dermatitis: a cross-sectional study in a tertiary referral centre |
| P5.17 16:50 | Fandresena Arilala SENDRASOA Pharmacists’ knowledge and practices about use of topical steroids in children with atopic dermatitis |
| Sept. 1st 10:00 | Poster session 2 |
| SCREEN A | |
| P8.17 10:00 | Rebecca POSPICH The T cell response to staphylococcal serine-protease like protein in atopic dermatitis patients |
| P9.1 10:05 | Nadia Oktafina PRAYITNO A Multiplex Immunoassay for Simultaneous Detection of Antimicrobial Peptide in the Stratum Corneum of Atopic Dermatitis Skin |
| P8.13 10:10 | Chang Ook PARK Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation |
| P8.15 10:15 | Wanjin KIM Microbiome analysis of bacteria and fungi in head and neck dermatitis in atopic dermatitis patients treated with dupilumab |
| P8.18 10:20 | Yu Ri WOO Increased expression of lipocalin correlates with disease activity of scalp dermatitis in patients with atopic dermatitis |
| P8.9 10:25 | Jiehyun JEON Serum level of Malassezia specific IgE antibody as a marker for severity of head and neck dermatitis in Korean atopic dermatitis patients |
| SCREEN B | |
| P8.6 10:00 | Krzysztof SITKO Clinical significance of circulating heat shock proteins in patients with atopic dermatitis |
| P11.5 10:05 | Anna ZARYCZAŃSKA The expression of IL-19 and IL-37 in the skin of atopic dermatitis patients |
| P8.2 10:10 | Alpana MOHTA Periostin and Interleukin-13: Independent Associations with Atopic Dermatitis |
| P8.11 10:15 | Arturo BORZUTZKY Alterations of the CD200/CD200R immunomodulatory pathway in skin and blood from patients with atopic dermatitis |
| P8.10 10:20 | Annie ZHANG Dupilumab Treatment Normalizes Intraepidermal Nerve Fiber Density in Patients with Moderate-to-Severe Atopic Dermatitis and Improves Patient-Reported Outcomes |
| SCREEN C | |
| P8.19 10:00 | Macarena TEJOS-BRAVO Effect of psychocosocial stress in patients with atopic dermatitis: relevance for somatosensory profile and small nerve fibers in chronic lesions |
| P8.14 10:05 | Sun Hye SHIN Identification of the impact of air pollutant-induced epigenetic changes on the development and exacerbation of atopic dermatitis |
| P8.20 10:10 | Weronika ZYSK The association between interleukin 35 gene single nucleotide polymorphisms and atopic dermatitis in the Polish population |
| P8.16 10:15 | Sailan WANG Exploring the role of the ADO gene in atopic dermatitis |
| P8.12 10:20 | Isabel TAPIA-PAEZ Searching for new candidate genes associated with Atopic Dermatitis in Ethiopians |
| SCREEN D | |
| P8.1 10:00 | Alpana MOHTA Exploring the Role of Leptin in Atopic Dermatitis: Insights from a Study of School-Children in Western India |
| P8.5 10:05 | Leszek BLICHARZ Enterotoxin Gene Cluster and selX Are Associated with Atopic Dermatitis Severity-A Cross-Sectional Molecular Study of Staphylococcus aureus Superantigens |
| P8.7 10:10 | Leszek BLICHARZ Gut microbial dysbiosis is associated with intestinal barrier damage and IgE-mediated food allergy in adult patients with atopic dermatitis |
| P8.4 10:15 | Yoonjin ROH The alleviation of particulate matter-exacerbated atopic derma-titis via exosomes derived from adipose tissue-sourced mesen-chymal stem cells |
| P8.3 10:20 | Argho Aninda PAUL Ubiquitin proteasome system (UPS) mediated degradation of profilaggrin and alternation of degron route, ubiquitin conjugating amino acids and stability of pathogenic FLG mutant protein |
| Sept. 1st 15:30 | Poster session 3 |
| SCREEN A | |
| P2.5 15:30 | Alpana MOHTA A case-control study of the assessment of COVID-19 severity in hospitalized children with atopic dermatitis |
| P2.6 15:35 | Shruti CHOPRA Identification and characterization of a novel possible genetic risk factor for eczema herpeticum |
| P2.7 15:40 | Dorota JENEROWICZ Pollen-food cross allergy in atopic dermatitis patients |
| P10.1 15:45 | Alpana MOHTA Sublingual Immunotherapy with Dermatophagoides Pteronyssinus (House Dust Mite) Extract for Atopic Dermatitis: A Placebo-Controlled Trial |
| P8.21 15:50 | Hiroyuki MUROTA Itch in atopic dermatitis is also induced by skin mobility by voluntary movement: lessons from a patient with amyotrophic lateral sclerosis |
| SCREEN B | |
| P2.8 15:30 | Fenohasina RAKOTONANDRASANA Profile of comorbidities associated with atopic dermatitis at the department of dermatology in Antananarivo Madagascar |
| P2.9 15:35 | Szymon MUĆKA Characteristics of atopic dermatitis in patients over 60 years of age – a prospective single centre study |
| P2.10 15:40 | Dong Hun LEE Cardiovascular Disease-Specific Proteomics of Korean Patients with Atopic Dermatitis Reveal Distinct Proteomic Signatures |
| P2.11 15:45 | Hae Chang JOH Systemic lupus erythematosus accompanied with atopic dermatitis: A case series report |
| P2.12 15:50 | Gloria Elisante MASENGA Anxiety and Depression among Adult Atopic Dermatitis Patients Attending the Regional Dermatology Training Center in Northern Tanzania 2023 |
| SCREEN C | |
| P3.2 15:30 | Anna ZARYCZAŃSKA Allergic contact dermatitis in patients with atopic dermatitis |
| P4.1 15:35 | Esmé KAMPHUIS Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study |
| P5.2 15:40 | Jiyoung AHN Mycosis Fungoides Found in Patients with Atopic Dermatitis Refractory to Dupilumab; Newly Defined “Eczematous Mycosis Fungoides” |
| P2.13 15:45 | Emilia MAJSIAK Skin rash, atopic dermatitis, Duhring’s disease and celiac disease: can they coexist? |
| P8.8 15:50 | Youin BAE Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis |
| SCREEN D | |
| P5.1 15:30 | Hyunchang KO Prophylactic use of diquafosol eye drops for dupilumab-associated conjunctivitis in patients with severe atopic dermatitis: An open-label prospective study |
| P2.14 15:35 | Sul Hee LEE Ocular comorbidities of patients with atopic dermatitis in adolescent to young adults – a retrospective, single center study |
| P10.2 15:40 | Aleksandra LESIAK The use of methotrexate in atopic dermatitis in pediatric population-preliminary data from Systemic Treatment Efficacy In Atopic Dermatitis In Young Children And Adolescents (STEADY) |
| P12.1 15:45 | Aleksandra LESIAK Does serotonin give happiness to the skin? Preliminary study in atopic dermatitis patients |
| P2.15 15:50 | Yu Ri WOO Risk of developing hypertension in atopic dermatitis patients receiving long-term and low dose cyclosporine: A nationwide population-based cohort study |
| Sept. 2nd 10:00 | Poster session 4 |
| SCREEN A | |
| P4.5 10:00 | Andreas WOLLENBERG Progressive and sustained disease control in patients with Atopic Dermatitis (AD) aged 12–17 years treated with tralokinumab for 52 weeks |
| P9.2 10:05 | Mike BASTIAN Dupilumab provides rapid improvements in signs, symptoms, and quality of life after the first dose |
| P10.9 10:10 | Andreas WOLLENBERG Evolution of EASI response with lebrikizumab in patients with moderate-to-severe atopic dermatitis: pooled results from two phase 3 trials (ADvocate1 and ADvocate2) at week 16 |
| P10.11 10:15 | Annie ZHANG Long-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis in an Open-Label Extension Study |
| P10.12 10:20 | Andreas WOLLENBERG Long-term efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis |
| SCREEN B | |
| P4.7 10:00 | Peter NILSSON Early Treatment Expectations with Abrocitinib Monotherapy: Week 4 Safety and Efficacy |
| P5.4 10:05 | Jowita SROKA-TOMASZEWSKA Result of treatment patients with atopic dermatitis – ineffectiveness dupilumab case series |
| P4.2 10:10 | Anne Rosalie SCHLÖSSER Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort |
| P4.11 10:15 | Alberto ALEGRE BAILO Description of super-responders to tralokinumab treatment in atopic dermatitis: a multicenter study |
| P10.8 10:20 | Annie ZHANG Efficacy and Safety of Dupilumab Treatment up to 1 Year in Infants and Preschool Children With Moderate-to-Severe Atopic Dermatitis |
| SCREEN C | |
| P10.7 10:00 | Aleksandra LESIAK Evaluation of the effectiveness and safety of the treatment with dupilumab in adult patients with severe atopic dermatitis in the B.124 program – the first real world evidence from one polish centre |
| P10.10 10:05 | Marie Louise SCHUTTELAAR Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial |
| P5.3 10:10 | Joo Yeon KO Is elevated serum immunoglobulin E (IgE) level a marker of treatment failure of JAK inhibitor in atopic dermatitis? : A case report |
| P4.3 10:15 | Sun Young CHOI Effects of Oral Administration of Lactiplantibacillus Plantarum APsulloc 331261 Isolated from Green Tea on Atopic Dermatitis-like Skin Lesion Mouse Models |
| P10.4 10:20 | Yi Na YOON Polyarthralgia and Serum Sickness Following Dupilumab Treatment in a Patient with Atopic Dermatitis: A Case Report |
| SCREEN D | |
| P10.6 10:00 | Annie ZHANG Dupilumab improves skin lipid composition in atopic dermatitis irrespective of patient filaggrin mutation status |
| P10.23 10:05 | Magdalena TRZECIAK The experiences from everyday life treatment of AD with Dupilumab – short time observation |
| P10.5 10:00 | Yang Won LEE Long-term efficacy and safety of dupilumab in real clinical practice : single center study |
| P4.6 10:15 | Magdalena TRZECIAK Temporal Response Patterns of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of the JADE DARE Trial |
| P10.3 10:20 | Jill OLYDAM Effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis: daily practice data |
Other posters
| P1.1 | Weronika MATWIEJUK Association Between Atopic Dermatitis and Epilepsy in Polish Population |
| P2.16 | Diana Libertad ORTEGA NÚÑEZ Clinical characteristics of adult patients with severe atopic dermatitis in Mexico |
| P2.17 | Daud MANZAR Safety and Efficacy of Nemolizumab for Pruritus: A Systematic Review and Meta-Analysis |
| P2.18 | Alpana MOHTA Dermatitis Neglecta with atopic dermatitis- the menace of unwashed dermatosis in neglected children! |
| P4.8 | Annie ZHANG Dupilumab improves skin lipid composition in atopic dermatitis irrespective of patient filaggrin mutation status |
| P4.9 | Jiayue ZHENG Assessment of Upadacitinib\’s Impact on Immune Parameters in a Cohort of Atopic Dermatitis Patients Over Six Months |
| P4.10 | Jesse L. CARLIN Itch and Sleep Improvements in a Pooled Analysis of Neurokinin-1 Receptor Antagonist Tradipitant in Atopic Dermatitis |
| P5.5 | Eleftheria TAMPOURATZI Accelerated clinical improvement of atopic dermatitis under upatacitinib closely associated with serum biomarkers decrease |
| P5.6 | Henrik BRANDI Additional costs related to oral Janus kinase inhibitor use in atopic dermatitis |
| P5.7 | Henrik BRANDI Incremental risk of adverse events with oral Janus kinase inhibitor use in atopic dermatitis and other indications: a systematic review and meta-analysis |
| P5.8 | Dea METKO Awareness of primary care providers about medical and mental health comorbidities, as well as the new advanced therapies for atopic dermatitis. A cross sectional survey from Ontario, Canada |
| P5.9 | Emmanuel SUNTRES Prevalence of Creatine Phosphokinase Elevation in Patients receiving Immunomodulatory Therapies for Atopic Dermatitis: A Systematic Review and Meta-Analysis |
| P5.10 | Mckenzie VAN EATON The Skin I’m In: associations of topical corticosteroid phobia in Canadian adults |
| P5.11 | Mari NAKANISHI Possible effects of oral Janus kinase inhibitors for dupilumab facial redness |
| P5.19 | Alpana MOHTA Comparison of ChatGPT and Dermatology Resident Performance in Dermatology Case Diagnosis |
| P5.20 | Alpana MOHTA Evaluation of ChatGPT’s Ability in Basic Dermatology: A Comparative Study with Final-Year Medical Students |
| P8.22 | Alpana MOHTA Investigating the Impact of Lactobacillus pentosus on Allergen-Sensitized Atopic Dermatitis in Children |
| P8.23 | Zafer E. OZTURK Rapid and sustained improvement in sleep quality, anxiety, and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment |
| P8.24 | Amalie Thorsti Møller RØNNSTAD A randomized controlled study using oral dicloxacillin + mometasone furoate 0.1% vs. mometasone furoate 0.1% in adults with atopic dermatitis |
| P8.25 | Yu Ri WOO The perturbed scalp skin microbiome in patients with atopic dermatitis |
| P9.3 | Jin Seon BANG Validity and Reliability of Itch Intensity Scales for Chronic Pruritus in Atopic Dermatitis and Chronic Urticaria |
| P9.4 | Brian M. CALIMLIM What Scores Correspond to Patient Satisfaction? Treatment Satisfaction Score Strata for Clinician- and Patient-Reported Outcome Measures in Atopic Dermatitis |
| P9.5 | Bark Lynn LEW Drug survival analysis of dupilumab in moderate to severe atopic dermatitis patients: A retrospective study |
| P9.6 | Eung Ho CHOI Diosmetin increases endogenous active glucocorticoid by activating local 11β-hydroxysteroid dehydrogenase type 1 and suppresses skin inflammation in a murine model of atopic dermatitis |
| P9.7 | Anne SOHRT PETERSEN Matching-adjusted indirect comparison of the efficacy of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis beyond week 16 |
| P9.8 | In Ho BAE / Chan Ho NA The Atopic Dermatitis Control Tool to measure long-term control of atopic dermatitis in Korean patients undergoing dupilumab treatment: a retrospective single-centre analysis over 3 years |
| P9.9 | Malgorzata MAJ Allergic contact dermatitis in patients with atopic dermatitis |
| P9.10 | Korey CAPOZZA The Mental Health Burden of Atopic Dermatitis From an International Survey of Patients |
| P9.11 | Katharina ZEISER Demographic encoded phenotypes in atopic dermatitis and related QoL- Cross sectional results from the ProRaD-study in 1011 patients |
| P9.12 | Klaudia SZYMCZAK Antibacterial photodynamic inactivation as a tool to combat Staphylococcus aureus released from infected human keratinocytes – a simplified in vitro atopic dermatitis model |
| P9.13 | Magdalena TRZECIAK Improvement of atopic dermatitis among Polish AD patients treated with mono- and complementary emollient plus therapy |
| P10.6 | Mette DELEURAN Long-Term Safety Data for Dupilumab in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis |
| P10.13 | Alpana MOHTA Multistrain Synbiotic and Vitamin D3 Supplements for the Treatment of Atopic Dermatitis in Infants under One Year of Age: A Randomized, Double-Blind Clinical Trial |
| P10.14 | Jin Seon BANG Variation in Hematological Parameters Associated with Janus Kinases 1 and 2 Inhibition in Two Patients |
| P10.15 | Annie ZHANG Real-World Clinical Treatment Outcomes in Children < 12 Years of Age with Moderate-to-Severe AD: Interim Results From PEDISTAD Registry |
| P10.16 | Gaëlle BÉGO-LE-BAGOUSSE Real-World Effectiveness of Dupilumab in Atopic Dermatitis – A Targeted Literature Review and Meta-Analysis |
| P10.17 | Andreas WOLLENBERG Clinical response of lebrikizumab by disease duration: results from two phase 3 monotherapy studies |
| P10.18 | Brian M. CALIMLIM Effect of Upadacitinib on intensity of scorad items and impacts to itch and sleep: analysis from the measure up 1 and measure up 2 studies |
| P10.19 | Tan NGUYEN Pediatric atopic dermatitis patients’ experiences with dupilumab injections |
| P11.1 | Kim THOMAS A new paradigm for conducting efficient, online eczema trials – the Rapid Eczema Trials project |
| P11.2 | Kim THOMAS Implementing the Eczema Care Online behavioural intervention – key features and cost-effectiveness |
| P12.2 | Joanna NAKONIECZNA Staphylococcus aureus from atopic dermatitis patients: similar or different?: characterization of genetic structure and susceptibility to killing by light-activated compound |
| P12.3 | Mendrika Fifaliana RAKOTOARISAONA Follicular eczema associated with traditional therapy in a Malagasy child |
Honour Patronages:
